Ipratropium Respiratory Pharmacology Guide

Short-acting muscarinic antagonists block parasympathetic stimulation of the airways. Unlike beta agonists, they reduce bronchoconstriction by preventing acetylcholine from activating muscarinic receptors on bronchial smooth muscle.

Ipratropium competitively blocks muscarinic M1, M2 and M3 receptors throughout the airways. Therapeutically, M3 blockade is most important because acetylcholine normally activates phospholipase C, generating IP3 and increasing intracellular calcium within bronchial smooth muscle. Blocking this pathway decreases calcium-mediated contraction, producing bronchodilation and reducing mucus secretion. Because ipratropium is a quaternary ammonium compound, systemic absorption is minimal and it does not significantly cross the blood-brain barrier.

Ipratropium should not be considered a rescue medication by itself. During severe asthma or COPD exacerbations it is combined with albuterol (DuoNeb or Combivent) because muscarinic blockade and beta-2 agonism produce additive bronchodilation. Stable COPD maintenance increasingly favors LAMA therapy, although ipratropium remains useful in selected patients.

Bronchodilation begins within approximately 3 to 15 minutes, peaks at 1 to 2 hours and generally lasts 4 to 6 hours. Less than 10 percent of an inhaled dose reaches systemic circulation. Oral absorption is extremely poor, protein binding is low, and most absorbed drug is eliminated by the kidneys. The limited systemic exposure explains the relatively low incidence of systemic anticholinergic adverse effects.

COPD maintenance therapy is typically 2 inhalations of Atrovent HFA four times daily or 500 mcg nebulized every 6 to 8 hours. During acute asthma or COPD exacerbations, 500 mcg nebulized ipratropium is administered every 20 minutes for three doses in combination with high-dose albuterol, followed by intermittent dosing as clinically indicated.

Avoid ocular exposure because accidental administration into the eyes may precipitate acute narrow-angle glaucoma. Use cautiously in patients with urinary retention, bladder outlet obstruction or benign prostatic hyperplasia. Rare paradoxical bronchospasm and hypersensitivity reactions require immediate discontinuation.

Concurrent anticholinergic medications may increase dry mouth, urinary retention and blurred vision. Ipratropium is routinely combined with beta-2 agonists such as albuterol because their mechanisms are complementary. Do not mix preservative-containing ipratropium solutions with cromolyn in the same nebulizer.

Monitor improvement in wheezing, dyspnea, FEV1, work of breathing and bronchodilator response. Assess inhaler or nebulizer technique, evaluate for urinary retention and ocular symptoms, and monitor frequency of rescue bronchodilator use.

These are the answer choices, mechanisms, or medication classes most commonly confused with this medication on RT school and NBRC-style exams.

• Short-acting beta agonist
• Long-acting muscarinic antagonist
• Inhaled corticosteroid
• Stimulates beta-2 receptors
• Primary rescue medication for exercise-induced bronchospasm

• COPD exacerbation treated with SABA plus SAMA
• Severe asthma exacerbation as adjunct bronchodilator
• COPD maintenance symptom control

• Combine with albuterol for severe exacerbations.
• Avoid spraying into the eyes.
• Monitor patients with urinary retention.
• Preferred over beta agonist alone in many COPD exacerbations.
• Not a replacement for inhaled corticosteroids in asthma.

• Confusing SAMA with LAMA.
• Choosing ipratropium as sole rescue therapy.
• Believing it is an anti-inflammatory medication.
• Forgetting narrow-angle glaucoma precautions.
• Confusing M3 blockade with beta-2 stimulation.

• SAMA identification
• Receptor physiology
• COPD guideline questions
• Drug comparison
• Clinical scenario interpretation